Roots Analysis

MAY 21, 2024

Over the last decade, one of the major challenges faced by pharmaceutical companies across the globe is low drug solubility. In fact, it has been observed that around 40% of the pharmaceutical drugs approved by regulatory organizations exhibit poor bioavailability / solubility.

Drug Delivery 40

Drug Delivery Drugs Gene Therapy Bioavailability 40

Roots Analysis

MARCH 13, 2022

In the last decade alone, the annual number of approvals of biopharmaceuticals (including monoclonal antibodies, recombinant proteins, vaccines and gene therapies), by the US FDA, have steadily risen. Over the years, the rising popularity of biologics has led to a paradigm shift in the healthcare industry. Our Social Media Platform.

Manufacturing 52

Manufacturing Drug Delivery Marketing Drug Delivery Systems 52

Drug Discovery World

AUGUST 3, 2022

Oligonucleotides act on the RNA level through different molecular pathways, but there is a major drawback when using them as drugs: their poor bioavailability and cellular uptake. Ensuring that the CPP can escape this endosomal compartment is crucial for its bioavailability and bioactivity properties. cells, such as diabetes.

Bioavailability 52

Bioavailability In-Vivo RNA In-Vitro 52

XTalks

AUGUST 30, 2022

One of the biggest challenges with developing therapies to treat CNS disorders is the delivery of systemically administered investigational products (IPs) to the brain, which is limited by the blood-brain barrier. Some methods of direct CNS administration include intrathecal, intraparenchymal and intracerebroventricular (ICV) delivery.

Trials 83

Trials Drug Delivery Drugs Gene 83